These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38410920)

  • 1. ADJUBIL: phase II study of adjuvant immunotherapy with STRIDE regimen with/without capecitabine in biliary tract cancers.
    Goetze T; Gonzalez-Carmona MA; Kochen L; Agaoglu NB; Al-Batran SE; Habibzada T; Pons M; Brunner M; Ettrich TJ; Köhne CH; Roderburg C; Modest D
    Future Oncol; 2024 Feb; 20(6):307-315. PubMed ID: 38410920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
    Oh DY; Lee KH; Lee DW; Yoon J; Kim TY; Bang JH; Nam AR; Oh KS; Kim JM; Lee Y; Guthrie V; McCoon P; Li W; Wu S; Zhang Q; Rebelatto MC; Kim JW
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):522-532. PubMed ID: 35278356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
    Boilève A; Hilmi M; Gougis P; Cohen R; Rousseau B; Blanc JF; Ben Abdelghani M; Castanié H; Dahan L; Tougeron D; Metges JP; Tournigand C; Garcia-Larnicol ML; Vernerey D; Turpin A; Neuzillet C
    Eur J Cancer; 2021 Jan; 143():55-63. PubMed ID: 33279854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with NAB
    Woodford R; Brungs D; Leighton C; Grimison P; Sjoquist KM; Becker T; Robinson S; Gebski V; Wilson K; Chantrill L; Aghmesheh M
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e220-e226. PubMed ID: 34180586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine Extends Survival for Biliary Tract Cancer.
    Cancer Discov; 2017 Jul; 7(7):OF1. PubMed ID: 28572460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
    Lamarca A; Edeline J; McNamara MG; Hubner RA; Nagino M; Bridgewater J; Primrose J; Valle JW
    Cancer Treat Rev; 2020 Mar; 84():101936. PubMed ID: 31986437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
    Primrose JN; Fox RP; Palmer DH; Malik HZ; Prasad R; Mirza D; Anthony A; Corrie P; Falk S; Finch-Jones M; Wasan H; Ross P; Wall L; Wadsley J; Evans JTR; Stocken D; Praseedom R; Ma YT; Davidson B; Neoptolemos JP; Iveson T; Raftery J; Zhu S; Cunningham D; Garden OJ; Stubbs C; Valle JW; Bridgewater J;
    Lancet Oncol; 2019 May; 20(5):663-673. PubMed ID: 30922733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials.
    Belkouz A; Wilmink JW; Haj Mohammad N; Hagendoorn J; de Vos-Geelen J; Dejong CHC; Homs MYV; Groot Koerkamp B; van Gulik TM; van Oijen MGH; Punt CJA; Klümpen H
    Crit Rev Oncol Hematol; 2020 Jul; 151():102975. PubMed ID: 32464483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
    Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.
    Rizzo A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):483-485. PubMed ID: 33307876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.
    Graham JS; Boyd K; Coxon FY; Wall LR; Eatock MM; Maughan TS; Highley M; Soulis E; Harden S; Bützberger-Zimmerli P; Evans TR
    BMC Res Notes; 2016 Mar; 9():161. PubMed ID: 26969121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence.
    Salani F; Vetere G; Rossini D; Genovesi V; Carullo M; Bartalini L; Massa V; Bernardini L; Caccese M; Cesario S; Graziani J; Grelli G; Mangogna F; Vivaldi C; Masi G; Fornaro L
    Liver Int; 2024 Oct; 44(10):2763-2772. PubMed ID: 39072988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.
    Cereda S; Milella M; Cordio S; Leone F; Aprile G; Galiano A; Mosconi S; Vasile E; Santini D; Belli C; Auriemma A; Novarino A; Vaccaro V; Martines C; Marino D; Lutrino SE; Palazzo V; Reinach B; Aldrighetti L; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):109-14. PubMed ID: 26659366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
    Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
    Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant and neoadjuvant chemotherapy for biliary tract cancer: a review of randomized controlled trials.
    Nakachi K; Gotohda N; Hatano E; Nara S; Takahashi S; Kawamoto Y; Ueno M
    Jpn J Clin Oncol; 2023 Nov; 53(11):1019-1026. PubMed ID: 37599063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
    Kornek GV; Schuell B; Laengle F; Gruenberger T; Penz M; Karall K; Depisch D; Lang F; Scheithauer W
    Ann Oncol; 2004 Mar; 15(3):478-83. PubMed ID: 14998852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp).
    Javle MM; Oh DY; Ikeda M; Yong WP; Hsu K; Lindmark B; McIntyre N; Firth C
    ESMO Open; 2022 Feb; 7(1):100314. PubMed ID: 34922298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
    Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.